Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 221 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hypersensitivity Response Clear all
Completed No phase listed Observational Accepts healthy volunteers

Neural and Visual Responses to Light in Bipolar Disorder: A Novel Putative Biomarker

NCT02048995
View directory record Official record
Conditions
Bipolar Depression
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 50 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 23, 2026, 6:31 PM EDT
Completed Not applicable Interventional Results available

The Effect of Omalizumab on Responses to Cat Allergen Challenge

NCT00604786
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
omalizumab, placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 23, 2026, 6:31 PM EDT
Completed Phase 2 Interventional Results available

Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)

NCT03562377
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tralokinumab, Placebo, Tdap vaccine, Meningococcal vaccine
Drug · Biological
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years to 54 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
39
States / cities
Fort Smith, Arkansas • Bakersfield, California • Beverly Hills, California + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 23, 2026, 6:31 PM EDT
Completed Phase 2 Interventional Results available

Omalizumab in the Treatment of Peanut Allergy

NCT00949078
View directory record Official record
Conditions
Food Allergy, Peanut Allergy
Interventions
omalizumab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Oct 23, 2026, 6:31 PM EDT
Completed No phase listed Observational

Immune Response in Hypersensitivity Pneumonitis

NCT03873649
View directory record Official record
Conditions
Hypersensitivity Pneumonitis
Interventions
Bronchoscopy with lavage
Other
Lead sponsor
Nabeel Hamzeh
Other
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Oct 23, 2026, 6:31 PM EDT
Completed Phase 2 Interventional Results available

Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD)

NCT02210780
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 64 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
42
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Long Beach, California + 39 more
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Oct 23, 2026, 6:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Randomized, Crossover Study to Assess the Effects of Dietary Fiber-containing Bars on Glucose and Insulin Responses

NCT03796286
View directory record Official record
Conditions
Blood Glucose, Insulin Sensitivity, Dietary Fiber
Interventions
Medium-fiber bar, High-fiber bar, Control bar (0 g fiber)
Other
Lead sponsor
Midwest Center for Metabolic and Cardiovascular Research
Other
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Boca Raton, Florida • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 23, 2026, 6:31 PM EDT
Completed No phase listed Observational

Vibration Response Imaging in Chronic Obstructive Pulmonary Disease and Asthma

NCT00542282
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Asthma
Interventions
Not listed
Lead sponsor
Deep Breeze
Industry
Eligibility
18 Years to 85 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2009 · Synced Oct 23, 2026, 6:31 PM EDT
Not listed Phase 4 Interventional

Dupilmuab for Atopic Dermatitis Monitored With Noninvasive Imaging.

NCT05265234
View directory record Official record
Conditions
Eczema, Atopic Dermatitis
Interventions
Dupilumab, Optical Coherence Tomography, Reflectance confocal microscopy
Drug · Device
Lead sponsor
OptiSkin Medical
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Oct 23, 2026, 6:31 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Disentangling Anxiety Sensitivity and Anxiety-induced Physiological Stress Response

NCT02372110
View directory record Official record
Conditions
Anxiety
Interventions
HPA, ANS stimulation, Placebo
Drug
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 23, 2026, 6:31 PM EDT
Completed Phase 2 Interventional

12-Week Study in Adult Subjects With Asthma

NCT01516073
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone Propionate
Drug
Lead sponsor
Dey
Industry
Eligibility
18 Years to 60 Years
Enrollment
629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 11, 2014 · Synced Oct 23, 2026, 6:31 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Pulses Consumption and Its Role in Managing Systemic Inflammation, Insulin Sensitivity and Gut Microbiome in Human

NCT04267705
View directory record Official record
Conditions
Insulin Sensitivity, Overweight or Obesity, Inflammatory Response
Interventions
Control, Black bean, Chickpea
Other
Lead sponsor
Clinical Nutrition Research Center, Illinois Institute of Technology
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 23, 2026, 6:31 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

NCT04821622
View directory record Official record
Conditions
Prostate Cancer
Interventions
talazoparib plus enzalutamide, Placebo plus enzalutamide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
45
States / cities
Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 6:31 PM EDT
Active, not recruiting Phase 2 Interventional

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

NCT04550494
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Castration-Resistant Prostate Carcinoma, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, HER2-Positive Breast Carcinoma, Locally Advanced Breast Carcinoma, Locally Advanced Gastric Carcinoma, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Ovarian Carcinoma, Locally Advanced Pancreatic Carcinoma, Locally Advanced Prostate Carcinoma, Metastatic Breast Carcinoma, Metastatic Gastric Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Ovarian Carcinoma, Metastatic Pancreatic Carcinoma, Metastatic Prostate Carcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Breast Carcinoma, Recurrent Gastric Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Talazoparib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
4
States / cities
Gainesville, Florida • Bethesda, Maryland • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 23, 2026, 6:31 PM EDT
Recruiting No phase listed Observational

Clinical Pre-screening Protocol for Ovarian Cancer

NCT03877796
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Drug Response Predictor® (DRP)
Device
Lead sponsor
Allarity Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
7
States / cities
Tampa, Florida • Atlanta, Georgia • Albuquerque, New Mexico + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 23, 2026, 6:31 PM EDT
Active, not recruiting No phase listed Observational

Monitoring Response to Orkambi in Cystic Fibrosis Lung Disease by Inhaled Xenon MRI

NCT02848560
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Hyperpolarized Xenon
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 12 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 23, 2026, 6:31 PM EDT
Completed Phase 2 Interventional Results available

Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer

NCT02649855
View directory record Official record
Conditions
Prostate Cancer, Prostate Neoplasms, Neoplasms, Prostatic
Interventions
PROSTVAC-V, PROSTVAC-F, Docetaxel
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 23, 2026, 6:31 PM EDT
Recruiting Phase 1Phase 2 Interventional

TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT07190300
View directory record Official record
Conditions
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Interventions
Tulmimetostat, Darolutamide, Abiraterone, Prednisone/Prednisolone, Androgen Deprivation Therapy (ADT)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
8
States / cities
Birmingham, Alabama • Iowa City, Iowa • Westwood, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 23, 2026, 6:31 PM EDT
Completed Phase 2 Interventional

Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol in Pediatric Subjects

NCT00685347
View directory record Official record
Conditions
Asthma, Bronchoconstriction
Interventions
Levalbuterol HFA MDI, Racemic Albuterol
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
6
States / cities
Long Beach, California • Denver, Colorado • Englewood, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 23, 2026, 6:31 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of DESF in Pediatric Subjects

NCT07703982
View directory record Official record
Conditions
Allergic Reaction
Interventions
DESF
Drug
Lead sponsor
Aquestive Therapeutics
Industry
Eligibility
7 Years to 17 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
7
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 23, 2026, 6:31 PM EDT
Recruiting Phase 2 Interventional

Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer

NCT07216248
View directory record Official record
Conditions
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Interventions
relugolix + ARPI., Intermittent- Relugolix or androgen deprivation therapy (ADT) + ARPI, relugolix or androgen deprivation therapy (ADT) + ARPI
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Male only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 23, 2026, 6:31 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

T-IR- Study to Understand the Effects of Testosterone and Estrogen on the Body's Response to the Hormone Insulin

NCT01686828
View directory record Official record
Conditions
Insulin Resistance, Type 2 Diabetes Mellitus, Obesity, Androgen Deficiency, Metabolic Disease
Interventions
Acyline, Testosterone 1.62% gel, Letrozole, Placebo gel (for Testosterone 1.62% gel), Placebo pill (for Letrozole)
Drug
Lead sponsor
University of Washington
Other
Eligibility
25 Years to 55 Years · Male only
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Oct 23, 2026, 6:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Study to Investigate Efficacy of Two Experimental Oral Rinses in Providing Long Term Relief From Pain Derived From Exposed Dentine in Response to Chemical, Thermal, Tactile, or Osmotic Stimuli.

NCT02651467
View directory record Official record
Conditions
Dentin Sensitivity
Interventions
Experimental Oral Rinse 1 (1.5% w/w KOX, 0ppm F, pH 7.0), Experimental Oral Rinse 2 (2.0% w/w KOX, 45ppm F, pH 4.5), Placebo Oral Rinse (0% w/w KOX 0ppm F, pH 4.5 )
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
221 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Oct 23, 2026, 6:31 PM EDT
Terminated Phase 1 Interventional

Effect of Acid Reflux on Respiratory Physiology During Exercise in Athletes With GER-Response to Acid Suppression

NCT00444236
View directory record Official record
Conditions
Exercise Triggered Asthma, Gastroesophageal Reflux
Interventions
Nexium, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Oct 23, 2026, 6:31 PM EDT